)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Clarity Pharmaceuticals
Clarity Pharmaceuticals (CU6) investor relations material
Clarity Pharmaceuticals Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary11 Aug, 2026
Vision and strategy
Aims to build a leading pharmaceutical biotech based on Australian scientific IP, targeting blockbuster markets with high unmet needs.
Focuses on discovery, rigorous clinical development, and commercialisation of innovative radiopharmaceuticals.
Key products and pipeline
Lead product 64Cu/67Cu-SAR-bisPSMA targets prostate cancer, offering both diagnostic and therapeutic applications.
Three FDA Fast Track designations granted for diagnostic and therapeutic indications in prostate cancer.
Pipeline includes SARTATE for neuroendocrine tumours, SAR-bisFAP for pan-cancer theranostics, and SAR-Bombesin for PSMA-negative prostate cancer.
Clinical trial highlights
64Cu-SAR-bisPSMA outperformed standard PSMA PET agents in lesion detection, uptake, and tumour-to-background ratio in multiple Phase I-III trials.
Next-day imaging with 64Cu-SAR-bisPSMA significantly increased lesion detection and changed clinical management in a high proportion of patients.
67Cu-SAR-bisPSMA therapy showed high PSA response rates and complete responses in metastatic castration-resistant prostate cancer with a favourable safety profile.
SARTATE demonstrated improved lesion detection and sensitivity over 68Ga-DOTATATE in neuroendocrine tumours.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Clarity Pharmaceuticals
- SAR-bisPSMA delivers superior prostate cancer detection and clinical impact, driving market differentiation.CU6
Investor presentation - $197.8M cash, robust clinical progress, and manufacturing expansion position for commercial launch.CU6Q3 2026 TU
- Net loss widened to $42.3M as R&D ramped up, but cash reserves rose to $136.5M after a major equity raise.CU6H2 2024
- Raised $203.6M, advanced Phase III trials, and strengthened pipeline for US commercialisation.CU6H2 2025
- Loss widened to $55.7 million as R&D ramped up, but cash reserves strengthened to $226.2 million.CU6H1 2026
- Clinical pipeline advances, strong capital raise, and US supply chain expansion drive growth.CU6AGM 2025
- $203M capital raise and positive clinical data drive progress toward commercialisation.CU6Q4 2025 TU
- Strong financials, clinical progress, and board diversity drive growth and commercial readiness.CU6AGM 2024
- Copper theranostics show strong efficacy, safety, and market potential in cancer care.CU6Investor Presentation
Next Clarity Pharmaceuticals earnings date
Q4 202624 Aug, 2026
Clarity Pharmaceuticals
Next Clarity Pharmaceuticals earnings date
Q4 202624 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage